Study of Copanlisib and Ketogenic Diet

  • End date
    Dec 15, 2022
  • participants needed
  • sponsor
    Columbia University
Updated on 15 December 2021
ejection fraction
measurable disease
follicular lymphoma


This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).


As the investigators recently reported ketogenic diet can suppress hyperinsulinemia associated with PI3K inhibitors, leading to potentiation of the anti-tumor effects of PI3K inhibitors. Copanlisib potently inhibits PI3Kα and PI3Kδ. It has been approved for the treatment of relapsed follicular lymphoma, based on ORR of 59% (84 of 142 patients). The CR rate in FL was 14%, and the median progression-free survival was 11.2 months. Copanlisib demonstrated encouraging clinical activity in marginal zone lymphoma (ORR 70% including 9% CR). While these results are clinically meaningful, FL and MZL inevitably develop resistance to copanlisib with time, even in those patients who initially respond to the therapy. Novel strategies to improve the efficacy of copanlisib in FL and MZL, by improving CR and PFS, may transform how to manage these incurable malignancies.

Condition Follicular Lymphoma, Endometrial Cancer
Treatment Ketogenic diet, Copanlisib
Clinical Study IdentifierNCT04750941
SponsorColumbia University
Last Modified on15 December 2021


Yes No Not Sure

Inclusion Criteria

Be willing and able to provide written informed consent for the trial
Be 18 years of age or older on day of signing informed consent
For lymphoma, patients should have measurable disease based on the Lugano Criteria
For FL patients must have received at least two lines of prior therapy. There is no upper limit for the number of prior therapies. Tumor tissues of all patients are encouraged to be submitted (optional) prospectively for whole or targeted exome sequencing of key cancer related genes, using the Columbia Combined Cancer Panel (CCCP) or a comparable sequencing platform, such as the MSK-IMPACT 468-gene oncopanel
For EC the patients must have recurrent/advanced tumor for which surgical or the systemic curative treatments, or standard therapeutic approaches are not available. The following histologic subtypes are eligible: endometrioid, serous, clear cell, undifferentiated /dedifferentiated, mucinous, squamous, transitional, not-otherwise specified, and mixed celltype
Fresh and or archived tumor tissues must be available to (a) establish the diagnosis of the respective malignancies as described in Inclusion Criteria, and (b) be investigated for biomarkers. Patients without historical material or fresh tissue biopsy that is adequate for both diagnosis and correlative studies will not be eligible for the clinical trial
Left Ventricular Ejection Fraction (LVEF) > 50%
A performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
Demonstrate adequate organ function. All screening labs should be performed within 14 days of treatment initiation
HIV positive patients will be eligible as long as the viral load by polymerase chain reaction (PCR) testing is undetectable
Female patients of childbearing potential must have a negative pregnancy test within 7 days prior to treatment start
Adequate contraception

Exclusion Criteria

The following treatments are prohibited: (a) Chemotherapy (including PI3K inhibitors and other approved or investigational drugs) and monoclonal antibody within 3 weeks; (b) radiotherapy within 2 weeks prior to entering the study; (c) systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs
Patients that have not recovered from adverse events due to chemotherapy agents administered more than 3 weeks earlier
Hypersensitivity to copanlisib or any of its excipients
Type I diabetes
Uncontrolled Type II diabetes mellitus (HbA1c> 7.5%)
Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin
Patients that received major surgery and have not recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients with active, clinically serious infections > CTCAE version 5 Grade 2
Patients with known active concurrent malignancy with the following exception: nonmelanoma skin cancer, prostatic intraepithelial neoplasia, or carcinoma in situ of the cervix, prostate cancer that responds to androgen deprivation therapy and has no progression of disease for at least 12 months. If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years
Uncontrolled hypertension, i.e., blood pressure (BP) of ≥ 150/90; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria
Concomitant use of strong CYP3A4 inhibitors (defined in the protocol)
Uncontrolled moderate to severe hypertriglyceridemia (TG>300 mg/dL)
Myocardial infarction within 6 months of cycle 1, day 1
Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see Appendix 5)
An ECG recorded at screening showing evidence of cardiac ischemia
Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction < 40% by multigated acquisition (MUGA) scan or < 50% by echocardiogram and/or magnetic resonance imaging (MRI)
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months before the start of study medication
Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through at least 30 days after the last dose of trial treatment
History of nephrolithiasis or nephrolithiasis incidentally discovered during CT screening. Known selenium deficiency
Body mass index (BMI) less than 20
An allergy or intolerance to egg, gluten or milk protein
History of serious or uncontrolled gout or hyperuricemia
Pregnancy, lactation, or breastfeeding
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigators' opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Major surgical procedure or significant traumatic injury within 28 days prior to Day 1 or anticipation of the need for major surgery during the course of study treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note